Sling Therapeutics, Inc., a US-based biopharmaceutical company, announced on Wednesday that it has named Jeffrey Kent, MD, FACG, FACP as its new chief medical officer (CMO), effective immediately.
In the new role, Dr Kent will head medical, clinical, and regulatory functions to support the global Phase 2b LIDS clinical trial assessing the safety, pharmacokinetics, and efficacy of linsitinib, a small molecule insulin-like growth factor I receptor (IGF-1R) inhibitor, to treat thyroid eye disease (TED).
Dr Kent has more than two decades of life sciences experience in clinical development, medical affairs and medical/commercial strategy. He has held the position of executive vice president, medical Affairs and Outcomes Research at Horizon Therapeutics, executive medical director at Astellas Pharma, global project head for HUMIRA at Abbott Laboratories and medical director at Searle Pharmaceuticals.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval